Table 3.
Glypican-3 expression and intensity in relation to clinicopathologic parameters in patients with malignant salivary gland tumor.
| Variable | N (%) | Glypican-3 expression |
P Value | Glypican-3 Intensity |
P Value | ||||
|---|---|---|---|---|---|---|---|---|---|
| Negative N (%) | Positive N (%) | Negative N (%) | Weak N (%) | Moderate N (%) | Strong N (%) | ||||
| T status | |||||||||
| T1+T2 | 18 (54.5) | 4 (22.2) | 14 (77.8) | 4 (22.2) | 1 (5.6) | 6 (33.3) | 7 (38.9) | ||
| T3+T4 | 15 (45.5) | 1 (6.7) | 14 (93.3) | 0.3 | 1 (6.7) | 2 (13.3) | 6 (40) | 6 (40) | 0.7 |
| N Status | |||||||||
| N0 | 27 (81.8) | 5 (18.5) | 22 (81.5) | 5 (18.5) | 2 (7.5) | 10 (37) | 10 (37) | ||
| N1 | 6 (18.2) | 0 (0) | 6 (100) | 0.5 | 0 ( ) | 1 (16.7) | 2 (33.3) | 3 (50) | 0.5 |
| M Status | |||||||||
| M0 | 30 (40.9) | 5 (16.7) | 25 (83.3) | 5 (16.6) | 3 (10) | 10 (33.3) | 12 (40.1) | ||
| M1 | 3 (9.1) | 0 (0) | 3 (100) | – | 0 ( ) | 0 ( ) | 2 (66.6) | 1 (33.4) | – |
| Stage | |||||||||
| I + II | 15 (45.4) | 4 (26.7) | 11 (73.3) | 4 (26.7) | 0 (0) | 5 (33.3) | 6 (40) | ||
| III + IV | 18 (54.6) | 1 (5.6) | 17 (94.4) | 0.1 | 1 (5.6) | 3 (16.7) | 7 (38.9) | 7 (38.9) | 0.7 |
| Histiologic grade | |||||||||
| I | 12 (36.3) | 3 (25) | 9 (75) | 3 (25) | 0 (0) | 4 (333) | 5 (41.4) | ||
| II | 11 (33.3) | 1 (9.1) | 10 (90.9) | 1 (9.09) | 2 (18.1) | 3 (27.2) | 5 (45.6) | ||
| III | 10 (30.4) | 1 (10) | 9 (90) | 0.2 | 1 (10) | 1 (10) | 5 (50) | 3 (30) | 0.9 |